These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 18511543

  • 1. VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis) in microvascular retinal endothelial cells.
    Deissler H, Deissler H, Lang S, Lang GE.
    Br J Ophthalmol; 2008 Jun; 92(6):839-43. PubMed ID: 18511543
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Inhibition of vascular endothelial growth factor (VEGF) is sufficient to completely restore barrier malfunction induced by growth factors in microvascular retinal endothelial cells.
    Deissler HL, Deissler H, Lang GE.
    Br J Ophthalmol; 2011 Aug; 95(8):1151-6. PubMed ID: 21273213
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of protein kinase C is not sufficient to prevent or reverse effects of VEGF165 on claudin-1 and permeability in microvascular retinal endothelial cells.
    Deissler HL, Deissler H, Lang GE.
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):535-42. PubMed ID: 19643968
    [Abstract] [Full Text] [Related]

  • 5. [Effect of VEGF165 and the VEGF aptamer pegaptanib (Macugen) on the protein composition of tight junctions in microvascular endothelial cells of the retina].
    Deissler HL, Lang GE.
    Klin Monbl Augenheilkd; 2008 Oct; 225(10):863-7. PubMed ID: 18951306
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Decursin inhibits VEGF-mediated inner blood-retinal barrier breakdown by suppression of VEGFR-2 activation.
    Kim JH, Kim JH, Lee YM, Ahn EM, Kim KW, Yu YS.
    J Cereb Blood Flow Metab; 2009 Sep; 29(9):1559-67. PubMed ID: 19536074
    [Abstract] [Full Text] [Related]

  • 8. Altered expression of genes related to blood-retina barrier disruption in streptozotocin-induced diabetes.
    Klaassen I, Hughes JM, Vogels IM, Schalkwijk CG, Van Noorden CJ, Schlingemann RO.
    Exp Eye Res; 2009 Jun 15; 89(1):4-15. PubMed ID: 19284967
    [Abstract] [Full Text] [Related]

  • 9. Binding of VEGF-A is sufficient to abrogate the disturbing effects of VEGF-B together with VEGF-A on retinal endothelial cells.
    Deissler HL, Lang GK, Lang GE.
    Graefes Arch Clin Exp Ophthalmol; 2015 Jun 15; 253(6):885-94. PubMed ID: 25663437
    [Abstract] [Full Text] [Related]

  • 10. Endostatin modulates VEGF-mediated barrier dysfunction in the retinal microvascular endothelium.
    Brankin B, Campbell M, Canning P, Gardiner TA, Stitt AW.
    Exp Eye Res; 2005 Jul 15; 81(1):22-31. PubMed ID: 15978251
    [Abstract] [Full Text] [Related]

  • 11. Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences.
    Deissler HL, Deissler H, Lang GE.
    Br J Ophthalmol; 2012 Jul 15; 96(7):1023-8. PubMed ID: 22539748
    [Abstract] [Full Text] [Related]

  • 12. [In vitro studies on the mechanism of action of VEGF and its inhibitors].
    Deissler HL, Lang GE.
    Klin Monbl Augenheilkd; 2008 Jul 15; 225(7):623-8. PubMed ID: 18642204
    [Abstract] [Full Text] [Related]

  • 13. Involvement of MAPKs in endostatin-mediated regulation of blood-retinal barrier function.
    Campbell M, Collery R, McEvoy A, Gardiner TA, Stitt AW, Brankin B.
    Curr Eye Res; 2006 Dec 15; 31(12):1033-45. PubMed ID: 17169842
    [Abstract] [Full Text] [Related]

  • 14. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo.
    Lowe J, Araujo J, Yang J, Reich M, Oldendorp A, Shiu V, Quarmby V, Lowman H, Lien S, Gaudreault J, Maia M.
    Exp Eye Res; 2007 Oct 15; 85(4):425-30. PubMed ID: 17714704
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Blocking of VEGF-A is not sufficient to completely revert its long-term effects on the barrier formed by retinal endothelial cells.
    Deissler HL, Rehak M, Busch C, Wolf A.
    Exp Eye Res; 2022 Mar 15; 216():108945. PubMed ID: 35038456
    [Abstract] [Full Text] [Related]

  • 17. Angiopoietin modulation of vascular endothelial growth factor: Effects on retinal endothelial cell permeability.
    Peters S, Cree IA, Alexander R, Turowski P, Ockrim Z, Patel J, Boyd SR, Joussen AM, Ziemssen F, Hykin PG, Moss SE.
    Cytokine; 2007 Nov 15; 40(2):144-50. PubMed ID: 17959386
    [Abstract] [Full Text] [Related]

  • 18. VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability.
    Harhaj NS, Felinski EA, Wolpert EB, Sundstrom JM, Gardner TW, Antonetti DA.
    Invest Ophthalmol Vis Sci; 2006 Nov 15; 47(11):5106-15. PubMed ID: 17065532
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Ranibizumab efficiently blocks migration but not proliferation induced by growth factor combinations including VEGF in retinal endothelial cells.
    Deissler HL, Deissler H, Lang GK, Lang GE.
    Graefes Arch Clin Exp Ophthalmol; 2013 Oct 15; 251(10):2345-53. PubMed ID: 23760670
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.